


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented): A compound of formula I



(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]-urea,

in which

- D denotes a mono- or bicyclic aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂ or -C≡CH,
- X denotes NR³ or O,
- Y denotes O, S, NH, N-CN or N-NO₂,
- R¹ denotes H, Ar, Het, or cycloalkyl,
- R¹ may also be A which is optionally mono-, di- or trisubstituted by OR², SR², S(O)_mR², SO₂N(R²)₂, SO₃R², S(=O)(=NR²)R², NR²SO₂R², OSO₂R², OSO₂N(R²)₂, N(R²)₂, CN, COOR², CON(R²)₂, Ar, Het or cycloalkyl,
- E denotes CH,
- Z is ethylene,
- Z' is ethylene,
- Q is absent or denotes O, NR², C=O, SO₂ or C(R²)_n,
- R² denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,
- R³ denotes H or A,

- R^1, R^4 each, independently of one another, is absent or denote A, OH or OA, or R^1 and R^4 together denote methylene or ethylene,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by =O, =S, =NH, =NR³, =NOR³, =NCOR³, =NCOOR³, =NOCOR³, R³, Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂NR² and/or S(O)_nA,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,
- Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²SO₂A, COR², SO₂N(R²)₂, -[C(R³)₂]_n-COOR², -O-[C(R³)₂]_n-COOR², SO₃H or S(O)_nA,
- Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R³)₂]_n-COOR³ or -O-[C(R³)₂]_n-COOR³,
- Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen (=O), =S, =N(R²)₂, Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-OR², -[C(R³)₂]_n-N(R³)₂, NO₂, CN, -[C(R³)₂]_n-COOR², -[C(R³)₂]_n-CON(R²)₂, -[C(R³)₂]_n-NR²COA, NR²CON(R²)₂, -[C(R³)₂]_n-NR²SO₂A, COR², SO₂N(R²)₂ and/or S(O)_nA,
- Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R³)₂, Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂ and/or S(O)_nA,
- Hal denotes F, Cl, Br or I,
- m denotes 1 or 2,
- n denotes 0, 1 or 2,
- o denotes 1, 2 or 3, and

p denotes 1, 2, 3, 4 or 5,

or a pharmaceutically usable salt thereof, or a stereoisomer thereof, including mixtures thereof in all ratios.

2. (Previously Presented): A compound according to Claim 1, in which D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR² or COOR², or pyridyl which is unsubstituted or monosubstituted by Hal.

3. (Previously Presented): A compound according to Claim 1, in which D denotes phenyl which is monosubstituted by Hal.

4. (Previously Presented): A compound according to Claim 1, in which R² denotes H or A.

5. (Previously Presented): A compound according to Claim 1, in which T denotes
a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), or
phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OR² or NR²COA, or a monocyclic unsubstituted, saturated carbocycle.

6. (Previously Presented): A compound according to Claim 1, in which Q is absent or denotes O or CH₂.

7. (Previously Presented): A compound according to Claim 1, in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², NR²COA, SO₂A, SO₂NH₂, COOR² or CN.

8. (Previously Presented): A compound according to Claim 1, according to Claim 1 in which Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³ or NR³COA.

9. (Previously Presented): A compound according to Claim 1, in which R¹ denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR².

10. (Previously Presented): A compound according to Claim 1, in which R¹ denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR³.

11. (Previously Presented): A compound according to Claim 1, in which Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O).

12. (Previously Presented): A compound according to Claim 1, in which Y denotes O.

13. (Previously Presented): A compound according to Claim 1, in which X denotes NR^{3*} or O, and R^{3*} denotes H.

14. (Cancelled):

15. (Previously Presented): A compound according to Claim 1, in which T denotes

a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle.

16. (Previously Presented): A compound according to Claim 1, in which A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F.
17. (Previously Presented): A compound according to Claim 1, in which
- D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR² or COOR², or pyridyl which is unsubstituted or monosubstituted by Hal,
 - X denotes NR³ or O,
 - Y denotes O,
 - R¹ denotes Ar, Het, cycloalkyl or A, which may be monosubstituted by OR²,
 - E denotes CH,
 - Z, Z' each denote ethylene,
 - Q is absent or denotes O or CH₂,
 - R² denotes H or A,
 - R³ denotes H or A,
 - R⁴, R^{4'} each, independently of one another, is absent or denote A, OH or OA, or R⁴ and R^{4'} together denote methylene or ethylene,
 - T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O), phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA, or a monocyclic unsubstituted, saturated carbocycle,
 - A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F,
 - Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², NR²COA, SO₂A, SO₂NH₂, COOR² or CN,
 - Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),
 - Hal denotes F, Cl, Br or I, and

p denotes 1, 2, 3, 4 or 5.

18. (Previously Presented): A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes $\text{NR}^{3'}$ or O,

Y denotes O,

R^1 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA, a monocyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms, or A, which may be monosubstituted by OR^3 ,

$\text{R}^{3'}$ denotes H,

E denotes CH_3 ,

Z, Z' each denote ethylene,

Q is absent or denotes O or CH_2 ,

R^2 denotes H or A,

R^3 denotes H or A,

R^4 , $\text{R}^{4'}$ each, independently of one another, is absent or denote A, OH or OA, or R^4 and $\text{R}^{4'}$ together denote methylene or ethylene,

T denotes a monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen ($=\text{O}$),

phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA ,
or a monocyclic unsubstituted, saturated carbocycle,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and

Hal denotes F, Cl, Br or I.

19. (Previously Presented): A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

X denotes $\text{NR}^{3'}$ or O,

Y denotes O,

- R¹ denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,
or
A, which may be monosubstituted by OR³,
- R³ denotes H or A,
- R^{3'} denotes H,
- E denotes CH,
- Z, Z' each denote ethylene,
- Q is absent or denotes O or CH₂,
- R² denotes H or A,
- R³ denotes H or A,
- R⁴, R^{4'} each, independently of one another, is absent or denote A, OH or OA, or R⁴ and R^{4'} together denote methylene or ethylene,
- T denotes piperidinyl, piperazinyl, pyridinyl, 2-oxopiperidin-1-yl, 2-oxopiperidin-4-yl, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, morpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxo-piperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, pyridazinyl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, where the radicals may additionally be monosubstituted by A,
phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA or NHCOA,
or a monocyclic unsubstituted, saturated carbocycle,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and
- Hal denotes F, Cl, Br or I.
20. (Previously Presented): A compound according to Claim 1, in which
- D denotes phenyl which is monosubstituted by Hal,

X denotes NR^3 or O,
 Y denotes O,
 R¹ denotes thienyl, furyl, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA,
 or
 A, which may be monosubstituted by OR^3 ,
 R³ denotes H or A,
 R^{3'} denotes H,
 E denotes CH,
 Z denotes ethylene,
 Z' denotes ethylene,
 Q is absent or denotes O or CH_2 ,
 R² denotes H or A,
 R³ denotes H or A,
 R⁴, R^{4'} is absent, or R⁴ and R^{4'} together denote methylene or ethylene,
 T denotes piperidin-1- or 4-yl, piperazinyl, morpholin-4-yl,
 each of which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O),
 or unsubstituted cyclohexyl,
 A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, and
 Hal denotes F, Cl, Br or I.

21. (Previously Presented): A compound according to Claim 1, wherein said compound is selected from:

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidiny1-1-yl)-2-oxo-1-phenylethyl]-urea,

(R)-1-(4-chlorophenyl)-3-[2-[4-(4-fluorophenoxy)piperidin-1-yl]-2-oxo-1-phenylethyl]urea ,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R,R)-1-(4-chlorophenyl)-3-{2-methoxy-1-[1-(1'-methyl-4,4'-bipiperidinyl-1-yl)-methanoyl]propyl}urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-hydroxy-4-(4-methoxyphenyl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea,

(R)-N-[4-(1-{2-[3-(4-chlorophenyl)ureido]-2-phenylethanoyl}piperidin-4-ylmethyl)-phenyl]acetamide,

(R)-1-(4-chlorophenyl)-3-{2-oxo-1-phenyl-2-[4-(1-phenylmethanoyl)piperidin-1-yl]-ethyl}urea,

(R,S)-1-[2-(3-benzylpiperidin-1-yl)-2-oxo-1-phenylethyl]-3-(4-chlorophenyl)urea,

(R,R)-1-(4-chlorophenyl)-3-(1-{1-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-methanoyl}-2-methoxypropyl)urea bistrifluoroacetate,

(R)-1-(2-4,4'-bipiperidinyl-1-yl-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-[2-4,4'-bipiperidinyl-1-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)-urea hydrochloride,

(R)-1-(2-4,4'-bipiperidinyl-1-yl-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea hydrochloride,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[1-(4-hydroxyphenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl]urea trifluoroacetate,

1-[2-[1,4']bipiperidinyl-1'-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-3-(4-chlorophenyl)-urea,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl]-urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-phenylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{1-(4-hydroxyphenyl)-2-[4-(4-methylpiperazin-1-yl)-piperidin-1-yl]-2-oxoethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-thiophen-2-ylethyl]urea trifluoroacetate,

(R)-1-(2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-thiophen-2-ylethyl)-3-(4-chlorophenyl)urea trifluoroacetate,

(R)-1-(4-chlorophenyl)-3-{2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-thiophen-2-ylethyl}urea bistrifluoroacetate,

(R)-1-(4-chlorophenyl)-3-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea,

(R)-1-(4-chlorophenyl)-3-[2-(4,4'-bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]-urea,

(R)-1-(4-chlorophenyl)-3-[1-(2-chlorophenyl)-2-(1'-methyl-2'-oxo-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea,

(R)-1-(4-chlorophenyl)-3-[1-phenyl-2-(1'-methyl-2'-oxo-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea,

2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)-carbamate,

2-4,4'-bipiperidinyl-1-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-carbamate hydrochloride,

2-4,4'-bipiperidinyl-1-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate hydrochloride,

1-(2-chlorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

1-(2-chlorophenyl)-2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxoethyl (R)-(4-chlorophenyl)carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-1-(2-chlorophenyl)-2-oxoethyl (R)-(4-chlorophenyl)-carbamate trifluoroacetate,

2-(4-morpholin-4-ylpiperidin-1-yl)-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)-
carbamate trifluoroacetate,

2-[1,4']bipiperidinyl-1'-yl-2-oxo-1-phenylethyl (R)-(4-chlorophenyl)carbamate
trifluoroacetate,

1-(2-chlorophenyl)-2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxoethyl (R)-(4-
chlorophenyl)carbamate bistrifluoroacetate,

2-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-oxo-1-phenylethyl (R)-(4-
chlorophenyl)carbamate bistrifluoroacetate,

1-(2,3-difluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate,

1-(2-fluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate,


1-(2-methoxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl (R)-(4-
chlorophenyl)carbamate,

and pharmaceutically usable ~~derivatives, solvates,~~ salts and stereoisomers thereof,
including mixtures thereof in all ratios.

22. (Previously Presented): A process for the preparation of a compound
according to Claim 1, said process comprising

- a) for the preparation of compounds
- X denotes NH and
- Y denotes O,

reacting a compound of formula II



with a compound of formula III



III,


or

b) for the preparation of compounds

in which


X and Y denote O,

reacting a compound of formula IV



IV,

with a compound of formula V



V

in which

X and Y denote O, and

L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or a base or acid of formula I is converted into one of its salts.

23. (Previously Presented): A method of inhibiting coagulation factor Xa in a patient, comprising administering to said patient an effective amount of a compound of claim 1.

24. (Previously Presented): A method of inhibiting coagulation factor VIIa in a patient, comprising administering to said patient an effective amount of a compound of claim 1.

25. (Previously Presented): A pharmaceutical composition comprising a compound according to Claim 1, and one or more excipients and/or adjuvants.

26. (Previously Presented): A pharmaceutical composition comprising a compound according to Claim 1, and at least one further medicament active ingredient.

27. (Cancelled):

28. (Previously Presented): A kit comprising a first and second separate packs, said first pack containing an effective amount of a compound according to Claim 1, and said second pack containing an effective amount of a further medicament active ingredient.

29. (Cancelled):

30. (Previously Presented): A compound according to claim 1, wherein Q is absent.

31. (Previously Presented): A compound according to claim 30, wherein X is NR^3 and Y is O.

32. (Previously Presented): A compound according to claim 30, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

33. (Previously Presented): A compound according to claim 31, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen

(=O).

34. (Previously Presented): A compound according to claim 30, wherein R¹ is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

35. (Previously Presented): A compound according to claim 33, wherein R¹ is phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, or OA.

36. (Previously Presented): A compound according to claim 30, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

37. (Previously Presented): A compound according to claim 35, wherein D is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl.

38. (Previously Presented): A method of treating a patient suffering from thrombosis comprising administering to said patient an effective amount of a compound according to claim 1.

39. (Cancelled):

40. (New): A compound according to claim 2, wherein T is piperidin-1- or 4-yl, which is unsubstituted or monosubstituted by A and/or carbonyl oxygen (=O).

41. (New): A compound according to claim 40, wherein T is piperidinyl, 2-oxopiperidin-1-yl, or 2-oxopiperidin-4-yl, which in each case is optionally monosubstituted by A.